US2020063121A1PendingUtilityA1

High Fidelity Restriction Endonucleases

Assignee: NEW ENGLAND BIOLABS INCPriority: Jul 12, 2007Filed: Sep 11, 2019Published: Feb 27, 2020
Est. expiryJul 12, 2027(~1 yrs left)· nominal 20-yr term from priority
C12N 9/22C12N 15/1034C12Q 1/44C12N 15/1086C12N 9/16C12N 15/1058
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.

Claims

exact text as granted — not AI-modified
1 - 43 . (canceled) 
     
     
         44 . A composition comprising a variant KpnI restriction endonuclease having reduced star activity, wherein the variant KpnI restriction endonuclease comprises an amino acid sequence that differs from the amino acid sequence of the parent KpnI restriction endonuclease by:
 (a) an amino acid substitution at one or more positions corresponding to positions 2, 16, 119, 132 and 134 in SEQ ID NO:87; or   (b) amino acid substitutions at positions corresponding to positions 16 and 148 in SEQ ID NO:87.   
     
     
         45 . The composition of  claim 44 , wherein the variant KpnI restriction endonuclease comprises an amino acid substitution at an amino acid position corresponding to position 16 in SEQ ID NO:87. 
     
     
         46 . The composition of  claim 45 , wherein the amino acid substitution is D16N. 
     
     
         47 . The composition of  claim 44 , wherein the variant KpnI restriction endonuclease comprises amino acids substitutions at amino acid positions corresponding to positions 16 and 148 in SEQ ID NO:87. 
     
     
         48 . The composition of  claim 47 , wherein the amino acid substitutions are D16N and D148E. 
     
     
         49 . The composition of  claim 44 , wherein the variant KpnI restriction endonuclease comprises amino acids substitutions at amino acid positions corresponding to positions 16, 132 and 148 in SEQ ID NO:87. 
     
     
         50 . The composition of  claim 49 , wherein the amino acid substitutions are D16N, E132A and D148E.

Join the waitlist — get patent alerts

Track US2020063121A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.